Axovant Sciences’ (AXON) “Hold” Rating Reiterated at Oppenheimer
AXON has been the topic of several other research reports. Zacks Investment Research upgraded shares of Axovant Sciences from a hold rating to a buy rating and set a $2.25 target price on the stock in a research note on Tuesday, October 9th. BidaskClub upgraded shares of Axovant Sciences from a strong sell rating to a sell rating in a research note on Tuesday, October 16th. ValuEngine upgraded shares of Axovant Sciences from a hold rating to a buy rating in a research note on Thursday, November 1st. Cowen restated a hold rating on shares of Axovant Sciences in a research report on Thursday, September 20th. Finally, HC Wainwright restated a buy rating and set a $7.00 price objective on shares of Axovant Sciences in a research report on Monday, August 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $4.56.
Shares of NASDAQ AXON opened at $1.95 on Friday. Axovant Sciences has a 52-week low of $1.02 and a 52-week high of $6.59. The company has a debt-to-equity ratio of 1.68, a quick ratio of 1.97 and a current ratio of 1.97.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Recommended Story: How Short Selling Works
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.